推薦產(chǎn)品
2-hydroxy-2-(pyrrolidin-2-yl)aceticacid 5-hydroxy-3,3-dimethyldihydrofuran-2(3H)-one methyl3-oxo-4-m-tolylbutanoate ethyl3-oxo-4-o-tolylbutanoate methyl2,4-dioxopentanoate 1H-pyrazolo[3,4-b]pyridine-3-carboxylicacid 5-(2,2,2-trifluoroethoxy)picolinicacid 2,3-dihydroxyterephthalicacid 4-(tert-butoxycarbonyl)morpholine-2-carboxylicacid 2-(4-fluorobenzyloxy)aceticacid 2-(2-fluorocyclohexyloxy)aceticacid 2-(tetrahydro-2H-pyran-4-yloxy)aceticacid 2-(pyridin-4-ylmethoxy)aceticacid 2-(cyclopentyloxy)aceticacid 2-(pyrazin-2-ylmethoxy)aceticacid 2-((4-(trifluoromethyl)pyridin-3-yl)methoxy)aceticacid 2-(pyridazin-3-yloxy)aceticacid 2-(pyridin-2-ylamino)aceticacid 2-(1H-pyrrolo[3,2-b]pyridin-3-yl)aceticacid 2-(1H-pyrrolo[2,3-c]pyridin-3-yl)aceticacid 2-(2-methyl-1H-imidazol-1-yl)aceticacid 2-(1H-indol-3-yl)propanoicacid 2-(1H-indol-1-yl)aceticacid 2-(1H-1,2,3-triazol-1-yl)aceticacid 2-(1H-benzo[d][1,2,3]triazol-1-yl)aceticacid ethyl2-bromo-2-phenylacetate ethyl2-bromo-2-(2-bromophenyl)acetate 1-(tert-butoxycarbonyl)azetidine-3-carboxylicacid 1-(benzyloxycarbonyl)pyrrolidine-3-carboxylicacid 1-tert-butyl3-methylazetidine-1,3-dicarboxylate 2-methylpyrido[2,3-b]pyrazin-3(4H)-one isothiazol-4-aminehydrochloride tert-butyl2-oxa-7-azaspiro[3.5]nonane-7-carboxylate 2-oxa-7-azaspiro[3.5]nonane 4-hydrazinylpyridin-2(1H)-one (7H-pyrrolo[2,3-d]pyrimidin-4-yl)methanaminehydrochloride 1-cyclopropylpiperazine 7-oxa-2-azaspiro[3.5]nonanehydrochloride 4,4-difluorocyclohexanaminehydrochloride 4-(1,3,4-oxadiazol-2-yl)aniline 4-(1,2,4-oxadiazol-3-yl)aniline 3,4-dihydro-2H-benzo[b][1,4]oxazine 3-(1-methyl-1H-pyrazol-4-yl)aniline piperazin-2-one methylpyrrolidine-3-carboxylate 2-(8-fluoronaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 6-(dimethylamino)-4-methylpyridin-3-ylboronicacid 3-bromo-7-chloro-5-methyl-1H-pyrazolo[4,3-b]pyridine 7-chloro-5-methyl-1H-pyrazolo[4,3-b]pyridine 5-bromo-3,3-dimethylindolin-2-one 市場(chǎng)行情 宏創(chuàng)控股4月13日發(fā)布2019年一季度業(yè)績(jī)預(yù)告，預(yù)計(jì)公司2019年1-3月凈利潤(rùn)為561.41萬(wàn)元～842.11萬(wàn)元，上年同期為116.96萬(wàn)元，同比增長(zhǎng)380%～620%。
公司表示，做出上述預(yù)測(cè)，是基于以下原因：公司2019年第一季度凈利潤(rùn)與上年同期相比同向上升,主要原因?yàn)楸緢?bào)告期內(nèi)公司主要產(chǎn)品產(chǎn)銷(xiāo)量、收入大幅增加致使毛利潤(rùn)增加及將濱州鴻博鋁業(yè)科技有限公司納入合并報(bào)表后對(duì)其應(yīng)收款項(xiàng)不再確認(rèn)逾期損失所致。
